HOTH News and Press, Hoth Therapeutics Inc. From 02/18/21

Hoth Therapeutics (HOTH) intends to expand the development of the HT-003 active pharmaceutical ingredient ((API)) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis.Hoth executed an option agreement with Is...

Greenland Technologies Holding Corporation (GTEC) +186% on signing co-operation agreement with SOCMA.Immunome (IMNM) +152% on discovery of antibodies neutralizing SARS-CoV-2 variants.Avinger (AVGR) +57%.Heritage Global (HGBL) +42%.U.S. Well Services (USWS) +35%.Cleveland BioLabs (CB...

Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs) HT-003 API will be investigated for potential therapeutic action for treatment of IBDs PR Newswire NEW YORK , ...

Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv Whitepaper is titled, "Transformations, Comparisons, Analysis of Down to Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Prot...

NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today it has initiated its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19. This study will investigate an updated construct, based on initial ...

Hoth Therapeutics ([[HOTH]] +9.6%) has signed an agreement with Camargo Pharmaceutical Services to facilitate the writing and submission of the Investigational New Drug application for its HT-001 topical product to the U.S. FDA for initiating the first clinical trial.The company will write, p...

Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients The IND submission will facilitate initiation of clinical trials for HT-001 in early 2022 PR Newswire NEW YORK , Feb. 8, 2021 /PRNewswire/ -- H...

Hoth Therapeutics (HOTH) provides pipeline updates and highlights that it has scheduled to start an early-stage clinical trial for its BioLexa Platform, designed for the treatment of atopic dermatitis, in the first quarter of 2021.The company has been granted a Pre-IND meeting ...

Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline PR Newswire NEW YORK , Feb. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipe...

Hoth Therapeutics (HOTH) announces extension of its research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent, for the treatment of acne.The 1-year agree...